Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How drug companies turned “depression” into a billion-dollar industry

Martha Rosenberg
Conditions
February 7, 2025
Share
Tweet
Share

Once upon a time, anxiety was anxiety. Maybe you were going for a root canal, taking a flight when you were a nervous flier, or meeting your in-laws for the first time, so you had “nerves.”

That was then. Sensing an untapped market, drugmakers who funded writers of the Diagnostic and Statistical Manual of Mental Disorders or “DSM” (the Bible for mental conditions) recast anxiety as “really depression,” and suddenly everyone was depressed. Significantly, since your anxiety was “really” depression, you needed to replace a medicine taken sporadically, as needed, with an antidepressant taken every day.

The discovery that people with real-life problems or occasional bad moods or days would willingly call themselves “depressed” made drugmakers Wall Street darlings. Stocks soared. No matter the sexual side effects from antidepressants, usually SSRIs, and their weight gain.

But there was more to come. Drugmakers then debuted the concept of “treatment-resistant depression.” If you weren’t deliriously happy on your new antidepressant, per a new mental “normal” defined by drugmakers, it wasn’t that you didn’t have depression in the first place; you had “treatment-resistant depression.”

Your first expensive drug needed to be coupled with more expensive drugs because monotherapy, one drug alone, wasn’t doing the trick. Enter the era of drug cocktails.

Then drugmakers and their DSM writers declared that depression was “progressive” and “chronic,” locking in patient customers for life and sometimes using fear marketing. Did anyone remember that before direct-to-consumer drug ads, depression was considered self-limiting, sometimes not even requiring medication? Apparently not.

The selling of depression was abetted by “patient” groups that declared anxiety and depression to be “mental illness.” Yes, mental illness! Suddenly, everyone was mentally ill. A tsunami of “behavioral” clinics, doctors who specialized in psych drugs, and even online platforms and apps urging you to love your mind (after you take your meds) ensued.

Today, a full fourth of U.S. women are on antidepressants. The full effect of such medication on the population’s collective mood and IQ is still unknown.

Today, with new drugs in the pipeline, legions of people on antidepressants are now told that they may really have “bipolar disorder,” which requires new expensive drugs. Or that they have “adult ADHD” (if they are restless or impulsive—and who isn’t?). If your child has ADHD, you also have an “ADHD family,” drugmakers now say.

Selling disease fears to sell drugs is unconscionable. But it has also convinced millions of healthy people they have and “want” a mental diagnosis. Yes, advertising works.

Martha Rosenberg is a health reporter and the author of Big Food, Big Pharma, Big Lies and Born With a Junk Food Deficiency.  

Prev

Why Canada won’t be the U.S.’s 51st state anytime soon

February 7, 2025 Kevin 0
…
Next

Physician suicide: Understanding the silent epidemic and finding solutions [PODCAST]

February 7, 2025 Kevin 0
…

Tagged as: Psychiatry

Post navigation

< Previous Post
Why Canada won’t be the U.S.’s 51st state anytime soon
Next Post >
Physician suicide: Understanding the silent epidemic and finding solutions [PODCAST]

ADVERTISEMENT

More by Martha Rosenberg

  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Conflicts of interest are eroding trust in U.S. health agencies

    Martha Rosenberg
  • The untold truths behind overdiagnosis and why it matters to your health

    Martha Rosenberg

Related Posts

  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Surviving medical school with depression

    Anonymous
  • The hidden cost of medical training: debt, depression, and despair

    Janet Constance Coleman-Belin
  • The complications of drug regulation

    Julie Craig, MD
  • Should drug use be decriminalized?

    Katya Korol and Sarah Fraser, MD
  • The promise of in silico drug development to improve patient outcomes

    Tanja Dowe

More in Conditions

  • Facing terminal cancer as a doctor and mother

    Kelly Curtin-Hallinan, DO
  • Why doctors must stop ignoring unintentional weight loss in patients with obesity

    Samantha Malley, FNP-C
  • Why hospitals are quietly capping top doctors’ pay

    Dennis Hursh, Esq
  • Why point-of-care ultrasound belongs in emergency department triage

    Resa E. Lewiss, MD and Courtney M. Smalley, MD
  • Why PSA levels alone shouldn’t define your prostate cancer risk

    Martina Ambardjieva, MD, PhD
  • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

    Olumuyiwa Bamgbade, MD
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How drug companies turned “depression” into a billion-dollar industry
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...